UBS Group
ABVC icon

UBS Group’s ABVC BioPharma ABVC Stock Holding History

UBS Group’s Portfolio ABVC Stock Details ABVC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.72K Sell
1,771
-817
-32% -$1.35K ﹤0.01% 9457
2025
Q4 		$5.51K Buy
2,588
+739
+40% +$1.98K ﹤0.01% 8673
2025
Q3 		$5.62K Buy
+1,849
New +$5.68K ﹤0.01% 8847
2025
Q2 		– Sell
-29,003
Closed -$30.7K – 10204
2025
Q1 		$30.7K Buy
29,003
+28,993
+289,930% +$17.6K ﹤0.01% 7929
2024
Q4 		$6 Buy
+10
New +$6 ﹤0.01% 9828
2023
Q1 		– Sell
-428
Closed -$2.69K – 9529
2022
Q4 		$2.69K Buy
+428
New +$3.16K ﹤0.01% 9635
2022
Q2 		– Sell
-127
Closed -$3K – 10232
2022
Q1 		$3K Sell
127
-639
-83% -$17K ﹤0.01% 9415
2021
Q4 		$26K Buy
+766
New +$24K ﹤0.01% 7529

Other funds holding ABVC

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return

UBS Group's ABVC Position: Q1 2026 in Review

UBS Group reduced its ABVC BioPharma (ABVC) stake by 32% in Q1 2026, selling an estimated $1.35K and leaving 1,771 shares worth $1.72K. The position accounts for ﹤0.01% of the portfolio, ranked #9457.

UBS Group first reported a position in ABVC in Q4 2021 and has held it in 8 quarters since. The position peaked at $30.7K in Q1 2025. 13 funds tracked by Wall St. Rank hold ABVC as of Q1 2026.

  • UBS Group held 1,771 shares of ABVC BioPharma worth $1.72K as of Q1 2026.
  • UBS Group sold 817 ABVC BioPharma shares in Q1 2026, an estimated $1.35K.
  • ABVC BioPharma made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #9457 holding.
  • UBS Group first reported a position in ABVC BioPharma in Q4 2021 and has held it in 8 quarters since.
  • UBS Group's ABVC BioPharma position peaked at $30.7K in Q1 2025.
  • 13 funds tracked by Wall St. Rank held ABVC BioPharma as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.